Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	755.86	709.17	517.55	137.64	298.4	171.45
Short-Term Investments	-	-	-	-	-	19.82
Cash & Short-Term Investments	755.86	709.17	517.55	137.64	298.4	191.27
Cash Growth	30.17%	37.02%	276.03%	-53.87%	56.01%	36.35%
Accounts Receivable	130.83	126.48	65.48	53.65	10.79	6.72
Other Receivables	0.47	1.79	0.54	-	-	-
Receivables	131.31	128.27	66.01	53.65	10.79	6.72
Inventory	34.93	37.17	19.54	15.64	6.81	7.87
Prepaid Expenses	15.58	17.39	20	12.05	4.32	3.92
Other Current Assets	2.72	2.04	0.51	0.35	0.49	0.33
Total Current Assets	940.39	894.03	623.61	219.33	320.81	210.11
Property, Plant & Equipment	2.85	2.97	3.58	3.7	3.62	3.98
Long-Term Investments	27.29	22.54	21.56	16.49	-	-
Other Intangible Assets	121.97	131.67	156.67	194.05	32.47	-
Long-Term Deferred Tax Assets	55.11	52.77	45.98	36.54	18.74	23.7
Other Long-Term Assets	-	-	-	-	-	0.01
Total Assets	1,148	1,104	851.41	470.11	375.63	237.79

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	7.15	11.2	16.59	14.8	3.98	2.77
Accrued Expenses	26.54	61.66	53.85	40.29	27.83	21.95
Current Portion of Leases	0.45	0.44	0.4	0.37	0.34	0.31
Current Income Taxes Payable	19.63	1.4	0.89	0.73	8.7	0.08
Other Current Liabilities	78.63	72.46	48.94	19.88	16.75	1.96
Total Current Liabilities	132.4	147.15	120.68	76.06	57.59	27.06
Long-Term Leases	2.24	2.35	2.79	3.19	3.56	3.89
Other Long-Term Liabilities	0.28	0.21	0.32	2.98	14.06	-
Total Liabilities	134.91	149.71	123.78	82.23	75.21	30.96

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.12	0.12	0.12	0.11	0.11	0.1
Additional Paid-In Capital	489.22	479.96	442.29	266.49	250.43	233.19
Retained Earnings	523.35	474.19	285.16	121.27	49.86	-26.31
Comprehensive Income & Other	0.01	-	0.06	0.01	0.02	-0.15
Shareholders' Equity	1,013	954.27	727.63	387.88	300.42	206.83
Total Liabilities & Equity	1,148	1,104	851.41	470.11	375.63	237.79

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	2.68	2.79	3.19	3.56	3.89	4.2
Net Cash (Debt)	753.18	706.38	514.37	134.08	294.5	187.06
Net Cash Growth	30.41%	37.33%	283.63%	-54.47%	57.43%	33.38%
Net Cash Per Share	5.92	5.55	4.12	1.18	2.64	1.74
Filing Date Shares Outstanding	122.38	122.12	121.45	117.86	105.65	102.74
Total Common Shares Outstanding	122.18	122.51	120.88	107.12	105.26	102.99
Working Capital	807.99	746.88	502.93	143.27	263.22	183.04
Book Value Per Share	8.29	7.79	6.02	3.62	2.85	2.01
Tangible Book Value	890.73	822.59	570.96	193.83	267.95	206.83
Tangible Book Value Per Share	7.29	6.71	4.72	1.81	2.55	2.01
Machinery	1.14	1.11	1.05	0.49	0.27	0.25
Leasehold Improvements	0.99	0.99	0.99	0.99	0.98	0.98

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: May 11, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error